OLAPARIB

Brand name:

• Lynparza®

Form and strength:

Please search for and view the medicine's Public Summary Document (PSD) for more information

Condition/indication:
(therapeutic use)

• Human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Listing requested:

Please see PSD for more information

Funding program:

Please see PSD for more information

Request authority level:

Please see PSD for more information

PBAC submission type:

Change to existing listing (Standard Re-entry Pathway)

Comment:

--

Submission sponsor:

Astrazeneca Pty Ltd

Other PBAC consideration:

• OLAPARIB

Submission received for:

November 2023 PBAC meeting

Opportunity for consumer comment:

Open 26/07/2023 and close 20/09/2023 (see PBS Website)

PBAC meeting:

Held on 01/11/2023

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

05/12/2023

Lodgement of required documentation:

15/12/2023

Acceptance of complete documentation:

Accepted

Agreement to listing arrangements:

Commenced on 21/12/2023

Status:

Finalised

Government processes:

Commenced on 08/04/2024

Medicine listed on the PBS:

01/07/2024 (see PBS schedule)

---